Cancer Research Institute Inc
- Assets
- $130.4m
- Revenue
- $33.7m
- Investments
- $64.6m
- Employees
- 36
- Location
- New York, NY
- Founding
- 11/1953
- Data as of
- 06/2022
- EIN
- 13-1837442
Organization Overview
Cancer Research Institute Inc is located in New York, NY. The organization was established in 1953. According to its NTEE Classification (H30) the organization is classified as: Cancer Research, under the broad grouping of Medical Research and related organizations. As of 06/2022, Cancer Research Institute Inc employed 36 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Cancer Research Institute Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 06/2022, Cancer Research Institute Inc generated $33.7m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 7 years, the organization has seen revenues fall by an average of (4.1%) each year. All expenses for the organization totaled $31.3m during the year ending 06/2022. You can explore the organizations financials more deeply in the financial statements section below.
Since 2015, Cancer Research Institute Inc has awarded 370 individual grants totaling $193,315,802. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990T
Mission & Program ActivityExcerpts From the 990T Filing
TAX YEAR
2022
Describe the Organization's Mission:
Part 3 - Line 1
SEE ON SCHEDULE OTHE CANCER RESEARCH INSTITUTE'S MISSION IS TO SAVE MORE LIVES BY FUELING THE DISCOVERY AND DEVELOPMENT OF POWERFUL IMMUNOTHERAPIES FOR ALL TYPES OF CANCER.
Describe the Organization's Program Activity:
CLINIC AND LABORATORY INTEGRATION PROGRAM: THE CRI CLINIC AND LABORATORY INTEGRATION PROGRAM (CLIP) SUPPORTS QUALIFIED SCIENTISTS WHO ARE WORKING TO EXPLORE CLINICALLY RELEVANT QUESTIONS AIMED AT IMPROVING THE EFFECTIVENESS OF CANCER IMMUNOTHERAPIES. THE PROGRAM FUNDS BASIC, PRECLINICAL, AND TRANSLATIONAL RESEARCH THAT CAN BE APPLIED DIRECTLY TO OPTIMIZING CANCER IMMUNOTHERAPY IN THE CLINIC. CLIP GRANTS PROVIDE UP TO $200,000 OVER TWO YEARS.
THE LLOYD J. OLD STAR PROGRAM, LAUNCHED IN 2019, PROVIDES GRANTS OF $1.25 MILLION OVER 5 YEARS TO MID-CAREER SCIENTISTS. THIS LONG-TERM FUNDING IS NOT TIED TO A SPECIFIC RESEARCH PROJECT, BUT RATHER AIMS TO PROVIDE A DEGREE OF FLEXIBILITY AND FREEDOM FOR INVESTIGATORS TO EXPLORE OUT-OF-THE-BOX AND DISRUPTIVE AVENUES OF RESEARCH. CANDIDATES SELECTED FOR THIS AWARD ARE EXPECTED TO BE FUTURE "STARS" IN THE FIELD OF CANCER IMMUNOLOGY: SCIENTISTS TAKING RISKS.
THE CRI IRVINGTON POSTDOCTORAL FELLOWSHIP PROGRAM, INCLUDING DESIGNATED FUNDING TO ENABLE GREATER RACIAL AND ETHNIC DIVERSITY AMONG SCIENTISTS WITHIN THE FIELD, PROVIDES SUPPORT TO FUND AND TRAIN YOUNG IMMUNOLOGISTS AND CANCER IMMUNOLOGISTS AT TOP UNIVERSITIES AND RESEARCH CENTERS AROUND THE WORLD. FELLOWS RECEIVE UP TO $175,500 OVER THREE YEARS TO COVER THE COST OF STIPEND OR SALARY, INSURANCE, AND OTHER RESEARCH-RELATED EXPENSES, SUCH AS TRAVEL TO CONFERENCES AND MEETINGS. OF THE MORE THAN 1,400 CRI POSTDOCTORAL FELLOWS FUNDED TO DATE, MANY HAVE SINCE BECOME HEADS OF MAJOR MEDICAL RESEARCH INSTITUTES, ACADEMIC LEADERS IN PRESTIGIOUS UNIVERSITIES, AND ADMIRED MENTORS TO THE NEXT GENERATION OF IMMUNOLOGISTS AND TUMOR IMMUNOLOGISTS.
THE CRI ANNA-MARIA KELLEN CLINICAL ACCELERATOR PROGRAM IS AN ACTIVELY MANAGED VENTURE PHILANTHROPY PROGRAM DESIGNED TO SPEED THE DEVELOPMENT OF CANCER IMMUNOTHERAPIES. THIS MODEL FACILITATES RESEARCH COLLABORATION ACROSS LEADING BIOPHARMA COMPANIES AND AMONG 90 OF THE WORLD'S TOP CANCER RESEARCHERS. THE PROGRAM AIMS TO IDENTIFY AND KICK-START DEVELOPMENT OF NEXT-GENERATION COMBINATION TREATMENTS USING THE MOST PROMISING DRUGS FROM DISPARATE COMPANIES. EACH PHILANTHROPIC INVESTMENT BRINGS A NEW CANCER TREATMENT TO PATIENTS, EMPOWERS ACADEMIC RESEARCHERS TO WORK MORE CLOSELY WITH INDUSTRY, AND CREATES THE POTENTIAL FOR SIGNIFICANT FUTURE RETURNS ON INVESTMENT BACK TO CRI TO MAKE THE PHILANTHROPIC VENTURE FUND SELF-SUSTAINING.TECHNOLOGY IMPACT AWARD: THE CRI TECHNOLOGY IMPACT AWARD PROVIDES SEED FUNDING OF UP TO $200,000 TO BE USED OVER 24 MONTHS TO ADDRESS THE GAP BETWEEN TECHNOLOGY DEVELOPMENT AND CLINICAL APPLICATION OF CANCER IMMUNOTHERAPIES.IMPACT GRANTS: CRI IMPACT GRANTS SUPPORT RESEARCH PROJECTS AND PUBLIC EDUCATION AND AWARENESS INITIATIVES WITHIN OR APPLICABLE TO THE FIELDS OF IMMUNOLOGY AND TUMOR IMMUNOLOGY FOR WHICH FUNDS HAVE BEEN SPECIFICALLY RAISED.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Jill O'donnell-Tormey PHD Ceo/dir. Of Scientific Affairs | Officer | 40 | $500,953 |
Alfred R Massidas Cfo/dir. Of Human Resources | Officer | 40 | $324,388 |
Lynne A Rapino Chief Program Officer | Officer | 40 | $268,914 |
Jay R Campbell Managing Dir. Of Cri Clinical Accelerator And Vent | Officer | 40 | $249,581 |
Sharon S Slade Chief Marketing Officer | Officer | 40 | $244,521 |
Brian M Brewer Chief Communications Officer | Officer | 40 | $200,270 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Sociedad Advertising Advertising | 6/29/22 | $211,989 |
Tic Toc Advertising Inc Advertising | 6/29/22 | $140,127 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $559,676 |
| Membership dues | $0 |
| Fundraising events | $675,506 |
| Related organizations | $0 |
| Government grants | $710,150 |
| All other contributions, gifts, grants, and similar amounts not included above | $26,788,333 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $28,733,665 |
| Total Program Service Revenue | $0 |
| Investment income | $548,584 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $21,476 |
| Net Gain/Loss on Asset Sales | $4,361,869 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $33,675,150 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $21,177,895 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $970,000 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $2,513,200 |
| Compensation of current officers, directors, key employees. | $680,053 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $1,702,495 |
| Pension plan accruals and contributions | $134,853 |
| Other employee benefits | $462,123 |
| Payroll taxes | $225,833 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $74,869 |
| Fees for services: Accounting | $95,472 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $468,783 |
| Fees for services: Other | $1,461,173 |
| Advertising and promotion | $617,905 |
| Office expenses | $323,548 |
| Information technology | $0 |
| Royalties | $0 |
| Occupancy | $461,187 |
| Travel | $77,382 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $45,164 |
| Insurance | $62,029 |
| All other expenses | $0 |
| Total functional expenses | $31,314,716 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $14,456,208 |
| Savings and temporary cash investments | $0 |
| Pledges and grants receivable | $28,317,202 |
| Accounts receivable, net | $39,970 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $426,189 |
| Net Land, buildings, and equipment | $142,209 |
| Investments—publicly traded securities | $22,457,949 |
| Investments—other securities | $64,598,585 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $130,438,312 |
| Accounts payable and accrued expenses | $712,546 |
| Grants payable | $62,989,463 |
| Deferred revenue | $0 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $31,541 |
| Total liabilities | $63,733,550 |
| Net assets without donor restrictions | $42,501,270 |
| Net assets with donor restrictions | $24,203,492 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $130,438,312 |
Grants Awarded
Over the last fiscal year, Cancer Research Institute Inc has awarded $21,171,105 in support to 39 organizations.
| Grant Recipient | Amount |
|---|---|
San Francisco, CA PURPOSE: RESEARCH | $3,644,000 |
Seattle, WA PURPOSE: RESEARCH | $1,867,282 |
Tampa, FL PURPOSE: RESEARCH | $1,825,500 |
Boston, MA PURPOSE: RESEARCH | $1,611,500 |
Redwood City, CA PURPOSE: RESEARCH | $1,425,500 |
WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY PURPOSE: RESEARCH | $1,250,000 |
Grants Recieved
Over the last fiscal year, we have identified 7 grants that Cancer Research Institute Inc has recieved totaling $8,050.
| Awarding Organization | Amount |
|---|---|
Tlgc Foundation Wilmington, DE PURPOSE: GENERAL & UNRESTRICTED | $5,000 |
Jun & Christine Qi Foundation San Jose, CA PURPOSE: TO SUPPORT CANCEL RESEARCHAND EDUCATION | $1,000 |
I J & Mary Larosa Memorial Foundation Inc Lincoln Park, NJ PURPOSE: TO FUND CANCERRESEARCH IMMUNOTHERAPY | $900 |
Pines Foundation Inc Charleston, SC PURPOSE: OPERATIONS | $500 |
Friends For A Better Way Foundation Columbia, MD PURPOSE: FUNDING SUPPORT | $350 |
Viener Foundation Inc Stuart, FL PURPOSE: GENERAL SUPPORT | $200 |
Endowment Analysis
| Beg. Balance | $10,885,794 |
| Earnings | -$1,053,125 |
| Net Contributions | $19,500 |
| Ending Balance | $9,852,169 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Dana Farber Mass General Brigham Cancer Care Inc Boston, MA | $42,647,489 | $95,186,368 |
Ludwig Institute For Cancer Research New York, NY | $25,811,385 | $89,264,708 |
Institute For Cancer Research Philadelphia, PA | $148,137,241 | $82,576,402 |
Wistar Institute Of Anatomy & Biology Philadelphia, PA | $414,460,000 | $115,831,000 |
American Association For Cancer Research Philadelphia, PA | $261,131,206 | $103,171,549 |
Nsabp Foundation Inc Pittsburgh, PA | $90,333,934 | $55,869,172 |
Cancer Research Institute Inc New York, NY | $130,438,312 | $33,675,150 |
Centre County Cancer Center State College, PA | $6,772,389 | $27,589,392 |
Nrg Oncology Foundation Inc Philadelphia, PA | $13,392,636 | $27,206,954 |
Lake Champlain Cancer Research Org Inc Essex Jct, VT | $0 | $292,033 |
Addgene Inc Watertown, MA | $22,116,271 | $23,985,910 |
Count Me In Inc Cambridge, MA | $7,331,909 | $8,017,841 |